Merck 2014 Annual Report Download - page 207

Download and view the complete annual report

Please find page 207 of the 2014 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 271

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200
  • 201
  • 202
  • 203
  • 204
  • 205
  • 206
  • 207
  • 208
  • 209
  • 210
  • 211
  • 212
  • 213
  • 214
  • 215
  • 216
  • 217
  • 218
  • 219
  • 220
  • 221
  • 222
  • 223
  • 224
  • 225
  • 226
  • 227
  • 228
  • 229
  • 230
  • 231
  • 232
  • 233
  • 234
  • 235
  • 236
  • 237
  • 238
  • 239
  • 240
  • 241
  • 242
  • 243
  • 244
  • 245
  • 246
  • 247
  • 248
  • 249
  • 250
  • 251
  • 252
  • 253
  • 254
  • 255
  • 256
  • 257
  • 258
  • 259
  • 260
  • 261
  • 262
  • 263
  • 264
  • 265
  • 266
  • 267
  • 268
  • 269
  • 270
  • 271

202 CONSOLIDATED FINANCIAL STATEMENTS → Notes to the Group accounts
(38) INVENTORIES
This item comprised:
€ million Dec. 31, 2014 Dec. 31, 2013
Raw materials and supplies 377.3 294.9
Work in progress 496.6 523.0
Finished goods 726.9 580.2
Goods for resale 58.9 76.1
1,659.7 1,474.2
Write-downs of inventories in 2014 amounted to €99.5 million
(2013: €94.1 million). In 2014, reversals of inventory write-downs
of €45.3 million were recorded (2013: €24.4 million). As of the
balance sheet date, no inventories were pledged as security for
liabilities.
(39) OTHER ASSETS
Other assets comprised:
€ million current non-current Dec. 31, 2014 current non-current Dec. 31, 2013
Other receivables 147.0 5.4 152.4 113.8 1.6 115.4
Derivative assets (operative) 468.5 2.9 471.4 72.7 53.9 126.6
Financial items 615.5 8.3 623.8 186.5 55.5 242.0
Receivables from non-income
related taxes 199.8 24.5 224.3 99.0 30.4 129.4
Prepaid expenses 53.8 17.1 70.9 34.9 12.2 47.1
Assets from defined benefit plans 1.8 – 1.8 3.8 – 3.8
Other assets 339.3 6.6 345.9 36.5 7.4 43.9
Non-financial items 594.7 48.2 642.9 174.2 50.0 224.2
1,210.2 56.5 1,266.7 360.7 105.5 466.2
Other receivables included current receivables from related parties
amounting to €76.5 million (2013: €32.5 million) as well as cur-
rent receivables from affiliates amounting to €0.9 million (2013:
€0.6 million). Interest receivables amounted to € 12.5 million
(2013: €30.6 million). In addition, other prepayments were reported
under this item. Other assets comprise the entitlement to the joint
marketing right for Xalkori® (crizotinib) with Pfizer Inc., USA, in
the amount of €294.4 million (see Note [5]).